Pasar al contenido principal

PAPEL DE MAPKS EN SARCOMA: IMPLICACIONES EN DIAGNOSTICO Y TERAPAI

RTI2018-094093-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

p38ß and Cancer: The Beginning of the Road

  • Roche, Olga
  • Fernández-Aroca, Diego M.
  • Arconada-Luque, Elena
  • García-Flores, Natalia
  • Mellor, Liliana F.
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
© 2020 by the authors., The p38 mitogen-activated protein kinase (MAPK) signaling pathway is implicated in cancer biology and has been widely studied over the past two decades as a potential therapeutic target. Most of the biological and pathological implications of p38MAPK signaling are often associated with p38α (MAPK14). Recently, several members of the p38 family, including p38γ and p38δ, have been shown to play a crucial role in several pathologies including cancer. However, the specific role of p38β (MAPK11) in cancer is still elusive, and further investigation is needed. Here, we summarize what is currently known about the role of p38β in different types of tumors and its putative implication in cancer therapy. All evidence suggests that p38β might be a key player in cancer development, and could be an important therapeutic target in several pathologies, including cancer., This work was supported by grants from Fundación Leticia Castillejo Castillo, Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094093-B-I00) to RSP and MJRH. OR holds a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH’s Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the FEDER. EAL holds a research predoctoral contract cofounded by the European Social Fund and the UCLM. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

p38ß (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models

  • Pascual-Serra, Raquel
  • Fernández-Aroca, Diego M.
  • Sabater, Sebastiá
  • Roche, Olga
  • Andrés, I.
  • Ortega-Muelas, Marta
  • Arconada-Luque, Elena
  • García-Flores, Natalia
  • Bossi, G.
  • Belandia, Borja
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
[Background and purpose]: Gemcitabine is an antitumour agent currently used in the treatment of several types of cancer with known properties as a radiosensitizer. p38MAPK signalling pathway has been shown to be a major determinant in the cellular response to gemcitabine in different experimental models. However, the molecular mechanism implicated in gemcitabine-associated radiosensitivity remains unknown., [Materials and methods]: The human sarcoma cell lines A673 and HT1080, and a mouse cell line derived from a 3-methylcholanthrene induced sarcoma were used as experimental models. Modulation of p38MAPKs was performed by pharmacological approaches (SB203580) and genetic interference using lentiviral vectors coding for specific shRNAs. Viability was assessed by MTT. Gene expression was evaluated by western blot and RT-qPCR. Induction of apoptosis was monitored by caspase 3/7 activity. Response to ionizing radiation was evaluated by clonogenic assays., [Results]: Our data demonstrate that chemical inhibition of p38MAPK signalling pathway blocks gemcitabine radiosensitizing potential. Genetic interference of MAPK14 (p38¿), the most abundantly expressed and best characterized p38MAPK, despite promoting resistance to gemcitabine, it does not affect its radiosensitizing potential. Interestingly, specific knockdown of MAPK11 (p38ß) induces a total loss of the radiosensitivity associated to gemcitabine, as well as a marked increase in the resistance to the drug., [Conclusion]: The present work identifies p38ß as a major determinant of the radiosensitizing potential of gemcitabine without implication of p38¿, suggesting that p38ß status should be analysed in those cases in which gemcitabine is combined with ionizing radiation., This work was supported by grants from Fundación Leticia Castillejo Castillo, Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094093-B-I00) to RSP and MJRH. OR holds a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH’s Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the FEDER. RSP is a researcher of CSIC temporarily adscribed to UCLM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential

  • Leal, Jorge
  • Santos, Lucía
  • Fernández-Aroca, Diego M.
  • Cuevas-Vicario, José Vicente
  • Martínez, M. Ángeles
  • Massaguer, Anna
  • Jalón, Félix A.
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
  • Rodríguez, Ana M.
  • Castañeda, Gregorio
  • Durán, Gema
  • Carrión, M. Carmen
  • Barrabés, Sílvia
  • Manzano, Blanca R.
The problems of resistance and side effects associated with cisplatin and other chemotherapeutic drugs have boosted research aimed at finding new compounds with improved properties. The use of platinum(IV) prodrugs is one alternative, although there is some controversy regarding the predictive ability of the peak reduction potentials. In the work described here a series of fourteen chloride Pt(II) and Pt(IV) compounds was synthesised and fully characterised. The compounds contain different bidentate arylazole heterocyclic ligands. Their cytotoxic properties against human lung carcinoma (A549), human breast carcinoma (MCF7) and human colon carcinoma (HCT116 and HT29) cell lines were studied. A clear relationship between the type of ligand and the anti-proliferative properties was found, with the best results obtained for the Pt(II) compound that contains an aniline fragment, (13), thus evidencing a positive effect of the NH2 group. Stability and aquation studies in DMSO, DMF and DMSO/water mixtures were carried out on the active complexes and an in-depth analysis of the two aquation processes, including DFT analysis, of 13 was undertaken. It was verified that DNA was the target and that cell death occurred by apoptosis in the case of 13. Furthermore, the cytotoxic derivatives did not exhibit haemolytic activity. The reduction of the Pt(IV) compounds whose Pt(II) congeners were active was studied by several techniques. It was concluded that the peak reduction potential was not useful to predict the ability for reduction. However, a correlation between the cytotoxic activity and the standard reduction potential was found., This work has been funded by the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-100709-B-C21 to BRM, RTI2018-100709-B-C22 to AM, RTI2018-094093-B-I00 to RSP), Junta de Comunidades de Castilla-La Mancha-FEDER (JCCM) (grant SBPLY/19/180501/000260 to BRM), Ministerio de Economía y Competitividad (Project PID2019-104381GB-I00 to GC), Fundación Leticia Castillejo Castillo to MJRH, Junta de Castilla y León, Consejería de Educación y Cultura y Fondo Social Europeo (Projects BU263P18 and BU087G19 to JVC) as well as UCLM-FEDER (grants 2019-GRIN-27183 and 2019-GRIN-27209 to BRM) and University of Girona (MPCUdG2016/076 to AM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology

  • Ortega-Muelas, Marta
  • Roche, Olga
  • Fernández-Aroca, Diego M.
  • Encinar, José Antonio
  • Albandea-Rodríguez, David
  • Arconada-Luque, Elena
  • Pascual-Serra, Raquel
  • Muñoz, Ismael
  • Sánchez-Pérez, Isabel
  • Belandia, Borja
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
© 2021 The Authors., Sorafenib is a multikinase inhibitor widely used in cancer therapy with an antitumour effect related to biological processes as proliferation, migration or invasion, among others. Initially designed as a Raf inhibitor, Sorafenib was later shown to also block key molecules in tumour progression such as VEGFR and PDGFR. In addition, sorafenib has been connected with key signalling pathways in cancer such as EGFR/EGF. However, no definitive clue about the molecular mechanism linking sorafenib and EGF signalling pathway has been established so far. Our data in HeLa, U2OS, A549 and HEK293T cells, based on in silico, chemical and genetic approaches demonstrate that the MEK5/ERK5 signalling pathway is a novel target of sorafenib. In addition, our data show how sorafenib is able to block MEK5-dependent phosphorylation of ERK5 in the Ser218/Tyr220, affecting the transcriptional activation associated with ERK5. Moreover, we demonstrate that some of the effects of this kinase inhibitor onto EGF biological responses, such as progression through cell cycle or migration, are mediated through the effect exerted onto ERK5 signalling pathway. Therefore, our observations describe a novel target of sorafenib, the ERK5 signalling pathway, and establish new mechanistic insights for the antitumour effect of this multikinase inhibitor., This work was supported by grants from Fundación Leticia Castillejo Castillo, Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094093-B-I00) to RSP and MJRH. OR holds a contract for accessing the Spanish System of Science, Technology, and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH's Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the FEDER. RPS and EAL hold a research predoctoral contract cofounded by the European Social Fund and UCLM. The Spanish Ministry of Economy and Competitiveness (MINECO, Project RTI2018-096724-B-C21) and the Generalitat Valenciana (PROMETEO/2016/006) support work in the Encinar´s laboratory. Authors are grateful to Dr.G- Ferrer Mayorga for her assistance in the transwell assays, and to the ‘Centro de Computación Científica’ (CCC-UAM) for letting us to take advantage of the computer cluster Cibeles (https://www.ccc.uam.es/) and for providing computing facilities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ERK5 Is a major determinant of chemical sarcomagenesis: implications in human pathology

  • Arconada-Luque, Elena
  • Jiménez-Suárez, Jaime
  • Pascual-Serra, Raquel
  • Hyun Nam-Cha, Syong
  • Moline, Teresa
  • Cimas, Francisco J.
  • Fliquete, Germán
  • Ortega-Muelas, Marta
  • Roche, Olga
  • Fernández-Aroca, Diego M.
  • Muñoz Velasco, Raúl
  • García-Flores, Natalia
  • Garnés-García, Cristina
  • Sánchez-Fdez, Adrián
  • Matilla-Almazán, Sofía
  • Sánchez-Arévalo Lobo, Víctor J.
  • Hernández-Losa, Javier
  • Belandia, Borja
  • Pandiella, Atanasio
  • Esparís-Ogando, Azucena
  • Ramón y Cajal, Santiago
  • Peso, Luis del
  • Sánchez-Prieto, Ricardo
  • Ruiz-Hidalgo, María J.
Sarcomas are a heterogeneous group of tumors in which the role of ERK5 is poorly studied. To clarify the role of this MAPK in sarcomatous pathology, we used a murine 3-methyl-cholanthrene (3MC)-induced sarcoma model. Our data show that 3MC induces pleomorphic sarcomas with muscle differentiation, showing an increased expression of ERK5. Indeed, this upregulation was also observed in human sarcomas of muscular origin, such as leiomyosarcoma or rhabdomyosarcoma. Moreover, in cell lines derived from these 3MC-induced tumors, abrogation of Mapk7 expression by using specific shRNAs decreased in vitro growth and colony-forming capacity and led to a marked loss of tumor growth in vivo. In fact, transcriptomic profiling in ERK5 abrogated cell lines by RNAseq showed a deregulated gene expression pattern for key biological processes such as angiogenesis, migration, motility, etc., correlating with a better prognostic in human pathology. Finally, among the various differentially expressed genes, Klf2 is a key mediator of the biological effects of ERK5 as indicated by its specific interference, demonstrating that the ERK5–KLF2 axis is an important determinant of sarcoma biology that should be further studied in human pathology., This work has been supported with Grant RTI2018-094093-B-I00 funded by MCIN/AEI/10.13039/501100011033, “ERDF A way of making Europe” to RSP. Also supported with funds from Fundación Leticia Castillejo Castillo, Roche España and ACEPAIN to RSP and MJRH. RSP and MJRH’s Research Institute and the work carried out in their laboratory, received partial support from the European Community through the FEDER. JJ and EAL hold a predoctoral research contract cofounded by the European Social Fund and UCLM. OR holds a contract for accessing the Spanish System of Science, Technology, and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ERK5 Is a Major Determinant of Chemical Sarcomagenesis, Implications in Human Pathology

  • Arconada-Luque, Elena|||0000-0002-2546-4157
  • Jiménez-Suarez, Jaime
  • Pascual-Serra, Raquel
  • Nam-Cha, Syong Hyun
  • Moliné, Teresa|||0000-0003-4912-5114
  • Cimas, Francisco J.|||0000-0001-9241-331X
  • Fliquete, Germán
  • Ortega-Muelas, Marta
  • Roche, Olga
  • Fernández-Aroca, Diego M.|||0000-0003-2699-7374
  • Muñoz Velasco, Raúl|||0000-0003-0621-167X
  • García-Flores, Natalia
  • Garnés-García, Cristina
  • Sánchez-Fdez, Adrián|||0000-0003-0678-9957
  • Matilla-Almazán, Sofía|||0000-0002-9090-0402
  • Sánchez-Arévalo Lobo, Víctor J.|||0000-0002-4561-1505
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Belandia, Borja
  • Pandiella, Atanasio|||0000-0002-4704-8971
  • Esparís-Ogando, Azucena|||0000-0003-4550-4192
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • del Peso, Luis
  • Sánchez-Prieto, Ricardo|||0000-0003-0882-9780
  • Ruiz-Hidalgo, María José|||0000-0003-2508-8398
Sarcoma is a heterogeneous group of tumors poorly studied with few therapeutic opportunities. Interestingly, the role of MAPKs still remains unclear in sarcomatous pathology. Here, we describe for the first time the critical role of ERK5 in the biology of soft tissue sarcoma by using in vitro and in vivo approaches in a murine experimental model of chemical sarcomagenesis. Indeed, our observations were extrapolated to a short series of human leiomyosarcoma and rhabdomyosarcomas. Furthermore, transcriptome analysis allows us to demonstrate the critical role of KLF2 in the biological effects of ERK5. Therefore, the data presented here open new windows in the diagnosis and therapy of soft tissue sarcomas. Sarcomas are a heterogeneous group of tumors in which the role of ERK5 is poorly studied. To clarify the role of this MAPK in sarcomatous pathology, we used a murine 3-methyl-cholanthrene (3MC)-induced sarcoma model. Our data show that 3MC induces pleomorphic sarcomas with muscle differentiation, showing an increased expression of ERK5. Indeed, this upregulation was also observed in human sarcomas of muscular origin, such as leiomyosarcoma or rhabdomyosarcoma. Moreover, in cell lines derived from these 3MC-induced tumors, abrogation of Mapk7 expression by using specific shRNAs decreased in vitro growth and colony-forming capacity and led to a marked loss of tumor growth in vivo. In fact, transcriptomic profiling in ERK5 abrogated cell lines by RNAseq showed a deregulated gene expression pattern for key biological processes such as angiogenesis, migration, motility, etc., correlating with a better prognostic in human pathology. Finally, among the various differentially expressed genes, Klf2 is a key mediator of the biological effects of ERK5 as indicated by its specific interference, demonstrating that the ERK5-KLF2 axis is an important determinant of sarcoma biology that should be further studied in human pathology.